ReviewCurrent oncology reports2026
Polypharmacy, Medicine Optimisation, and Medication Adherence in Older Cancer Patients.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPolypharmacy is highly prevalent among elderly with cancer due to multimorbidity, supportive medications, and complex treatment regimens. It poses challenges of adverse drug reactions, drug–drug interactions, and adherence difficulties. This review explores the epidemiology, clinical consequences, and strategies for medication optimisation and adherence support in geriatric oncology. RECENT
findingsEmerging evidence demonstrates that pharmacist-led medication reviews, comprehensive geriatric assessment, and tools such as STOPP/START, Beers Criteria, and the FORTA list improve prescribing quality and facilitate deprescribing. Digital health interventions, including telemonitoring and connected pill systems, enhance adherence. Artificial intelligence and machine learning–based predictive models are beginning to identify patients at risk of adverse drug events or non-adherence, although integration into oncology work flows remains limited. Polypharmacy and non-adherence remain major barriers to optimal cancer care in older adults. Multidisciplinary optimisation, combined with digital and AI innovations, offers a pathway to safer and more effective treatment.
Indexed as
Identifiers
42029748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.